Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

@article{Paya2002PreemptiveUO,
  title={Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.},
  author={Carlos V. Paya and Jennie Wilson and Mark J. Espy and Irene G Sia and Michael J DeBernardi and Thomas F. Smith and Robin Patel and Greg Jenkins and William Scott Harmsen and David J. Vanness and Russell H. Wiesner},
  journal={The Journal of infectious diseases},
  year={2002},
  volume={185 7},
  pages={854-60}
}
The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to prevent infection and disease in solid-organ transplant patients has not been evaluated by placebo-controlled trials. We carried out such a study in 69 patients who had received liver transplants and had positive results of CMV polymerase chain reaction within 8 weeks after transplantation but did not have concomitant CMV infection or disease. These patients were randomly assigned to receive placebo or oral… CONTINUE READING